VERSION 1 -REVIEW
In Section 5, the authors provide a definition of EM and reference Figure 3 but this section is confusing. The authors refer to EM as complementary to SR but then in Figure 3 it is a subset of SR-this figure should have a more informative caption. Based on what I understood, the main difference between EGM and EM are the goals. EGM is about finding a gap to guide future research while EM is about drawing conclusions based on the visual evidence. This should be more clearly stated. The other difference seems to be the use of tables in EGM and graphs is EM. What are the multiple factors that can be visualized simultaneously?
REVIEWER
Jose M. Ordonez-Mena Nuffield Department of Primary Care Health Sciences, University of Oxford, Unit ed Kingdom REVIEW RETURNED 01-Nov-2017
GENERAL COMMENTS
The authors have written a protocol for a very comprehensive systematic review and meta-analysis of all the evidence for the therapy of patients with recurrent pancreatic cancer. The authors propose using a new methodology to perform an evidence mapping. I feel the motivation for the use of this new methodology should be better defended, especially taken into account that there are many other methods available (see reference 32). I several other minor comments and suggestions for improvement:
1) The authors should define the objectives in more detail (at the moment just three lines). In particular, the authors should highlight what is the main objective and what are secondary ones.
2) The authors will be comparing many different treatments and therefore should consider the feasibility of conducting a network metaanalysis to summarise the evidence for all treatments at once instead of a traditional pairwise meta-analysis. An alternative would be to group all treatments within categories (i.e. all chemotherapies, radiotherapies, etc.) provided the heterogeneity or variability in the efficacy between treatments in the same category is small. 3) In section 1.1: the authors should consider using standard nomenclature for the different study designs included i.e. cross-sectional (descriptive and analytical), case-control (retrospective and prospective i.e. nested case control and case-cohort studies), cohort studies (retrospective and prospective) and clinical or experimental trials (randomised and non-randomised studies). The authors missed including non-experimental (or observational) double-armed prospective studies i.e. cohort studies in Figure 3 needs more information (either on the figure description or in the methods) to explain the overlap between the different methods used in summarising or describing the evidence. 13) Egger's test for publication bias is mentioned in the abstract but not in the methods. Please correct. Also note that this test requires a minimum of studies to have sufficient power to detect the bias.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 1-1. The object of this study was to compare the treatment option for RePC. The treatment option was decided by the pattern of recurrence and condition of patients. If multiple site of recurrence was evident, surgical resection was not usually selected, and for single lung metastasis, BSC was an inadequate treatment strategy. Thus the treatment method was strongly influenced by the condition of patients and the selection bias could be a problem. In this point, simple comparison of the treatment option was has not good impact for RePC. I think treatment strategy should be compared around the same back ground groups.
Reply #1-1. Thank you for pointing out important issue. As you mentioned, even in the same group with metastatic recurrence, the treatment options will affected by the condition of patients or the burden of disease. Because this is very important point, we updated study objectives and reflected it in the secondary objectives. We also reflected this into the method section.
[OBJECTIVES] 2. Secondary objectives (2) To explore the trends of RePC treatment by several era, based on important points including introductions of new CTx regimens or new OP techniques.
[METHODS]
We will perform another type of subgroup analysis by specific era, because the treatment paradigm has changed according to several important regimens such as FOLFIRINOX or nab-paclitaxel. The improvement of surgical techniques will also be considered as well as the improvement of chemotherapy.
1-2. Second, the data source of this study was several searching system and the duration was set from their inception to March 2017. I think the duration of study was too long. Chemotherapy for pancreatic cancer was dramatically changed when Gemcitabine/nab-paclitaxel and FOLFIRINOX was usually available. If the chemotherapy include the traditional regimen before these new regimen, comparing the chemotherapy with other type of recurrence was not useful for future planning of treatments. Though authors try to demonstrated the subgroup analysis according to the regimen of chemot herapy, but now the first line of chemotherapy was new regimen such as gemcitabine/nab-paclitaxel or FOLFIRINOX. I think it might be a good study design if the study duration was shorten after the new strong regimens were started.
Reply #1-2. Thank you. We agree to your comment, and the function of 'subgroup mapping for selected periods' is added the PLOEM version 2.0. Please note Reply #1-3.
1-3. Finally, authors demonstrated the usefulness of PLOEM for making the evidence mapping. But I could not understand the usefulness of this system only reading this protocol. Author should demonstrated the priority of this system more detailed using the past literature.
Reply #1-3. Thank you for your comment. We also think the plain manual of PLOEM is necessary. Currently, the factors that can be visualized simultaneously in the version of PLOEM 1.0 includes (1) research ID by numbering, (2) research title with PMID by mouse-rollover, (3) research design by different dot styles, (4) publication year by timeline (horizontal axis), (5) multiple treatment options by vertical axis, (6) direct links to the study by clicking the mouse, and (7) downloading of data extraction file (Microsoft excel form). Now we are developing the PLOEM version 2.0. and its manual. In the PLOEM version 2.0, more factors such as (8) networking for comparative studies, (9) listing the candidate studies for quantitative meta-analysis, (10) subgroup mapping for selected period, (11) uploading of data extraction file (Microsoft excel form), and (12) overviewing the non-adjusted pooled overall survival by treatment modalities will be visualized in a single screenshot. We summarized the upgrade items of PLOEM version 2.0 in Supplementary table 1. However, the final version of PLOEM 2.0 will be launched in accordance with the main SR-EM-MA, not the protocol. Please note that we are unable to release the final screen user interface (UI) yet.
1-4. How to treat with the crossover of patients. Several patients might be treated by chemotherapy, radiation therapy before best supportive care, or chemotherapy after surgical resection. How to treat with these patients.
Reply #1-4.
As we mentioned in Method section, the crossover treatment is classified as the 'first' treatment option. For example, if one patients received (CRT → CTx → BSC), he or she will be regarded as the CRT group. For more clarification for readers, we added this mention in Method section.
[METHOD]
In patients with multiple and serial treatment modality, the classification is according to the 'first' treatment option. For example, if one patients received (CRT → CTx → BSC), he or she will be regarded as the CRT group.
1-5. Established the definition of locoregional recurrence.
The area of locoregional recurrence were sometimes different by each study. Please clarify it. And clarify how to define the locoregional recurrence with remnant cancer.
Reply #1-5. Thank you. As we mentioned in Method section, locoregional recurrence and remnant tumor are in different category. Please refer to the exclusion criteria of section 1-3.
In terms of population composition, we will exclude the following researches: studies for (1) patients with pancreatic tumours other than PDAC, (2) patients who have previously undergone initial pancreatic surgery with a palliative or explorative, rather than curative, aim, and (3) patients who had remnant PC after surgery, or incomplete resection.
Reviewer 2 Overall I judge the protocol of good quality and worthy of publication, after minor revisions. I have few comments to the authors.
2-1. Despite pancreatic cancer being a leading cause of death, its survival in resected cases has significantly improved over the years, mainly due to pancreatic surgery centralisation.
Reply #2-1. Thank you for your comment. We agree to your point and apply the improvement of surgery in the subgroup analysis as below.
2-2. Despite large long term population studies confirm persistently low OS, there is increasing evidence that aggressive neoadjuvant chemotherapy and cheoratiotherapy and radical surgery can achieve 5 year OS rates higher than 7%. This fact does actually increases the need for the study, hence it would be important to better mention the post-surgery survival in resectable and locally advanced pancreatic cancer.
Reply #2-2. Thank you very much. We fully agree your point and this is why we perform SR-EM-MA, not a conventional MA only. We will explore the subgroup analysis by specific period, and updated the study objectives.
2-3. 3. A very short expansion of the method and function of the PLOEM tool would help understanding and reproducing its use. A short paragraph describing the actual coding functions and mathematic formulas, behind the user interface.
Reply #2-3. Thank you for your comment. The current version of PLOEM 1.0 can visualize the following factors simultaneously: (1) research ID by numbering, (2) research title with PMID by mouse-rollover, (3) research design by different dot styles, (4) publication year by timeline (horizontal axis), (5) multiple treatment options by vertical axis, (6) direct links to the study by clicking the mouse, and (7) downloading of data extraction file (Microsoft excel form). Now we are developing the PLOEM version 2.0., and more factors such as (8) networking for comparative studies, (9) listing the candidate studies for quantitative meta-analysis, (10) subgroup mapping for selected period, (11) uploading of data extraction file (Microsoft excel form), and (12) overviewing the non-adjusted pooled overall survival by treatment modalities will be visualized in a single screenshot of PLOEM version 2.0. We summarized the upgrade items of PLOEM version 2.0 in Supplementary table 1. However, the final version of PLOEM 2.0 will be launched in accordance with the main SR-EM-MA, not the protocol. Please note that we are unable to release the final screen user interface (UI) yet.
Reviewer 3 3-1. The review plan is comprehensive and complete. I had just some questions about EM. In Section 5, the authors provide a definition of EM and reference Figure 3 but this section is confusing. The authors refer to EM as complementary to SR but then in Figure 3 it is a subset of SRthis figure should have a more informative caption. Based on what I understood, the main difference between EGM and EM are the goals. EGM is about finding a gap to guide future research while EM is about drawing conclusions based on the visual evidence. This should be more clearly stated.
Reply #3-1.
Thank you for your comment. We also think that the discrepancy between the manuscript and Figure  3 and ambiguity of the Figure 3 itself confuse the readers. After the several co-authors' meeting, we decided to remove this figure in this protocol for several reasons.
(1) The scope of this picture is very broad and goes beyond the subject of this paper. (2) Reply #3-2. Thank you for your comment. The factors that can be visualized simultaneously in the version of PLOEM 1.0 includes (1) research ID by numbering, (2) research title with PMID by mouse-rollover, (3) research design by different dot styles, (4) publication year by timeline (horizontal axis), (5) multiple treatment options by vertical axis, (6) direct links to the study by clicking the mouse, and (7) downloading of data extraction file (Microsoft excel form). Now we are developing the PLOEM version 2.0, and more factors such as (8) networking for comparative studies, (9) listing the candidate studies for quantitative meta-analysis, (10) subgroup mapping for selected period, (11) uploading of data extraction file (Microsoft excel form), and (12) overviewing the non-adjusted pooled overall survival by treatment modalities will be visualized in a single screenshot of PLOEM version 2.0. We summarized the upgrade items of PLOEM version 2.0 in Supplementary table 1. However, the final version of PLOEM 2.0 will be launched in accordance with the main SR-EM-MA, not the protocol. Please note that we are unable to release the final screen user interface (UI) yet.
Reviewer 4 4-0. The authors have written a protocol for a very comprehensive systematic review and metaanalysis of all the evidence for the therapy of patients with recurrent pancreatic cancer. The authors propose using a new methodology to perform an evidence mapping. I feel the motivation for the use of this new methodology should be better defended, especially taken into account that there are many other methods available (see reference 32).
Reply #4-0. First of all, we deeply appreciate your essential, practical, and detailed comments. As you noted, the motivation for PLOEM is the important point for our study, but it was not sufficient in the original draft. This is because the capabilities of current PLOEM version 1.0 are still limited. We believe that much of this shortcoming will be resolved with PLOEM version 2.0 which we are now developing (Supplementary table 1) . Once again, we would like to thank you for your detailed comments and we will response by item in the reply below.
4-1. I several other minor comments and suggestions for improvement:
The authors should define the objectives in more detail (at the moment just three lines). In particular, the authors should highlight what is the main objective and what are secondary ones.
Reply #4-1. Thank you for your mention. We have updated our research objectives as follows.
[OBJECTIVES] 1. Main objectives This SR-EM-MA aims to visualize and structuralize the trends and efficacies of t he five treatment options, including ReOP, CTx, RTx, BSC, and ONT, for RePC after curative resection, using the novel automatic mapping device PLOEM. 4-2. The authors will be comparing many different treatments and therefore should consider the feasibility of conducting a network meta-analysis to summarise the evidence for all treatments at once instead of a traditional pairwise meta-analysis. An alternative would be to group all treatments within categories (i.e. all chemotherapies, radiotherapies, etc.) provided the heterogeneity or variability in the efficacy between treatments in the same category is small.
Reply #4-2. We appreciate your comment. As you noted, we should consider the feasibility of conducting a network meta-analysis. This was reflected in the Secondary objectives in the Objective part.
[OBJECTIVES] 2. Secondary objectives (3) If possible, to conduct the meta-analyses or network meta-analyses in the eligible comparative studies after checking the feasibility of the quantitative meta-analyses. 4-3. In section 1.1: the authors should consider using standard nomenclature for the different study designs included i.e. cross-sectional (descriptive and analytical), case-control (retrospective and prospective i.e. nested case control and case-cohort studies), cohort studies (retrospective and prospective) and clinical or experimental trials (randomised and non-randomised studies). The authors missed including non-experimental (or observational) double-armed prospective studies i.e. cohort studies in Table 1 . Only double-armed prospective experimental studies are included. Furthermore, case-series may sometimes include data for more than 10 patients. For a better distinction of case series and cohort studies see: #14. https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874 -017-0391-8 http://annals.org/aim/fullarticle/1033260/distinguishing -case-s eries-from-cohort-studies Reply #4-3. Thank you for the kind and comprehensive comments. We updated the categorization and nomenclature for the study designs. These have been reflected in Section 1.1., Table 2 (previously  Table 1 ). and citation list as follows.
[METHODS] In this context, we will include almost kinds of study designs such as case reports, case series, crosssectional (descriptive and analytical) studies, case-control (retrospective and prospective i.e. nested case control and case-cohort studies), cohort studies (retrospective and prospective) and clinical or experimental trials (randomised and non-randomised studies). To visualize and structuralize these designs intuitionally, we re-classified and summarized all the study types in Table 2 . To distinguish between case series and cohort studies, we will follow the definition of Methes et al.45, and Dekkers el al.46 4-4. Exclusion criteria in a systematic review should refer to the studies and not to the patients. Some studies partly include the participants that the investigators aim to exclude and so, there should be a criterion for dealing with these studies. For example, what would the investigators do if a study included a small percentage of patients with PDAC? Should this study be excluded or included?
Reply #4-4. Thank you for your comment. We updated the related section.
[MEHODS]
According to study design, we will not exclude any kinds of studies because this review aims to comprehensive mapping for treatment of RePC. If a study includes a diverse population and the PDAC is only a part of the study, we will ask the author for the original data. If this is not feasible, we will include the study only in visual mapping (EM), but we will exclude it from quantitative analysis of efficacy or toxicity.
In terms of population composition, we will exclude the following researches: studies for (1) patients with pancreatic tumours other than PDAC, (2) patients who have previously undergone initial pancreatic surgery with a palliative or explorative, rather than curative, aim, and (3) patients who had remnant PC after surgery, or incomplete resection. Reply #4-5. We appreciate your very important comment. We will explore treatment trends according to (1) use of treatment, (2) efficacy over time, and (3) side effects of treatments. We revised related sections, and we believe that your wise comments will enhance the quality of this review.
[METHODS] 1-4. Outcome measures Because this review is basically an EM, the outcome measure is visualization of mapping itself. However to structuralize the detailed trends, we will explore treatment trends according to (1) use of treatment, (2) efficacy (overall survival) over time, and (3) side effects of treatments.
If there are feasible studies for quantitative analysis, we will conduct the meta-analysis or network meta-analysis. In this case, the primary outcome will include overall survival (OS).
4-6. Evidence mapping is now dealt with in three different sections in the methods: sections 4, 5 and 7. Consider summarising into just one section. Define Evidence Mapping before introduc ing the new tool. Regarding the tool itself, after trying myself, I think it may not be that easy to use and reproducibility may be doubtful. In particular, in situations in which there are many studies and the investigator has to input the values for each study one by one. There is an option to export data to a spreadsheet but not to import a spreadsheet, which would make the generation of the plot easier and more reproducible as new studies appear or need to be excluded.
Reply #4-6. Thank you. We summarized three separated sections into one section and defined EM before introducing the new tool. Please refer to the revised manuscript. Regarding to PLOEM itself, your point -evaporation of the inserted data -is the weakest point of PLOEM version 1.0. However, now we are developing the PLOEM ver 2.0, and this problem will be resolved. Importing and exporting the 'excel file data' will be also available. We summarized the upgrade items of PLOEM version 2.0 in Supplementary table 1. However, the final versi on of PLOEM 2.0 will be launched in accordance with the main SR-EM-MA, not the protocol. Please note that we are unable to release the final screen user interface (UI) yet.
4-7. "
The statistical heterogeneity is expected to very high…" what sources of het erogeneity or variability in the effect sizes can the authors anticipate and how will they deal with them i.e. subgroup analyses/meta-regression? Why are RevMan and STATA used? Is Review Manager used for double-armed studies (for Odd Ratios and Relative Risks) and STATA for meta-analysis of survival rates (or risks)? What do the authors mean by "… MA itself will serve as a subgroup analysis in this study."?
Reply #4-7. Thank you for the comments. First, our expectation for higher heterogeneity is based the on the clinical characteristics of RePC, not on the statistical reason. Our pilot search also showed the possibility of higher heterogeneity. We also expect, unfortunately, that subgroup analyses/metaregression would not be available, because comparative designs of studies are scarce. (Back to the essence of EM again, if these analyses were possible, we would have tried a traditional MA. Because this is not possible, we perform an SR-EM, as an alternative trial. We removed the phrases about STATA and 'MA itself will…" because these could confuse readers. We modified the related sections as follows.
[METHODS] 7.2. Heterogeneity analysis Based on the clinical characteristics of RePC and our pilot search, the heterogeneity among studies is expected to be very high. If possible, heterogeneity among studies will be evaluated using I2 statistics, with 30%, 50%, and 75% as the cut-off points for low, moderate, and high degrees of heterogeneity, respectively.56 4-8. The authors use a great deal of non-standard abbreviations. Please, provide a list of abbreviations at the beginning or end of the protocol for reference. Consider eliminating some of the less used or less relevant abbreviations e.g. ReOp (re-operation is still one word). Please, also check for consistency ReOP refers to re-resection on page 4 and re-operation on page 6. Reply #4-8. Thank you. We added the Table 1 . as a list of abbreviations at the beginning of the protocol. Reoperation was changed into re-resection. Reply #4-9. This is summarized at the end of manuscript. Please refer the 3. Contributors. (We know that Korean naming is not familiar for Western researchers. For example in Hyoung Woo Kim, 'Hyoung Woo' is the first name, and 'Kim' is the last name.) One mistake (HJK) was corrected into HK in Method section. Reply #4-10. Thank you very much. Frankly, our co-authors have argued over this issue. We will follow your recommendations and thank you sincerely.
[METHODS] 3. Assessment of the risk of bias in included studies For NRSs of interventions, we will use ROBINS-I tool.48 For survival rates of single arm studies, we will use the risk of bias in prevalence studies tool by Hoy et al.49
4-11. In section 3, the last two sentences relating to quantitative analysis seem irrelevant to the risk of bias assessment. Delete or move to relevant section? Reply #4-11. We agree to you and removed the two sentences. Figure 3 needs more information (either on the figure description or in the methods) to explain the overlap between the different methods used in summarizing or describing the evidence.
4-12.
Reply #4-12. Thank you. After the several co-authors' meeting, we decided to remove this figure in the protocol section for several reasons. (1) The scope of this picture is very broad and goes beyond the subject of this paper. (2) It is somewhat unreasonable to summarize a single picture with the concept not yet fully maturated or established. (3) It is appropriate to use this picture in a final SR-EM-MA project, not a protocol, or proceed to a separate research topic. 4-13. Egger's test for publication bias is mentioned in the abstract but not in the methods. Please correct. Also note that this test requires a minimum of studies to have sufficient power to detect the bias.
Reply #4-13. Thank you for the kind and detailed comment. We expect that Egger's test for publication bias will be suitable for this study design. We therefore removed the sentences. Please refer to Abstract. Thank you very much.
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